Levodopa‐induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment
AUTOR(ES)
Thanvi, Bhomraj
FONTE
BMJ Group
RESUMO
Levodopa is the most effective drug for treating Parkinson's disease. However, long‐term use of levodopa is often complicated by significantly disabling fluctuations and dyskinesias negating its beneficial effects. Younger age of Parkinson's disease onset, disease severity, and high levodopa dose increase the risk of development of levodopa‐induced dyskinesias (LID). The underlying mechanisms for LID are unclear though recent studies indicate the importance of pulsatile stimulation of striatal postsynaptic receptors in their pathogenesis. The non‐human primates with MPTP‐induced parkinsonism serve as a useful model to study dyskinesia. Once established, LID are difficult to treat and therefore efforts should be made to prevent them. The therapeutic and preventative strategies for LID include using a lower dosage of levodopa, employing dopamine agonists as initial therapy in Parkinson's disease, amantadine, atypical neuroleptics, and neurosurgery. LID can adversely affect the quality of life and increase the cost of healthcare.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2600052Documentos Relacionados
- Low serum uric acid levels and levodopa-induced dyskinesia in Parkinson's disease
- Metoclopramide and pimozide in Parkinson's disease and levodopa-induced dyskinesias.
- Gamma vinyl GABA in the treatment of levodopa-induced dyskinesias in Parkinson's disease.
- Levodopa-induced dyskinesia and thalamotomy.
- Abnormal eye-head coordination in Parkinson's disease patients after administration of levodopa: a possible substrate of levodopa-induced dyskinesia.
